BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1974962)

  • 1. In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan's disease) by proton spectroscopy.
    Grodd W; Krägeloh-Mann I; Petersen D; Trefz FK; Harzer K
    Lancet; 1990 Aug; 336(8712):437-8. PubMed ID: 1974962
    [No Abstract]   [Full Text] [Related]  

  • 2. Localized 1H NMR spectroscopy in Canavan's disease: a report of two cases.
    Austin SJ; Connelly A; Gadian DG; Benton JS; Brett EM
    Magn Reson Med; 1991 Jun; 19(2):439-45. PubMed ID: 1881331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of localized proton nuclear magnetic resonance spectroscopy in Canavan's disease.
    Aydinli N; Calişkan M; Calay M; Ozmen M
    Turk J Pediatr; 1998; 40(4):549-57. PubMed ID: 10028864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPONGY DEGENERATION OF WHITE MATTER: CANAVAN'S SCLEROSIS.
    SACKS O; BROWN WJ; AGUILAR MJ
    Neurology; 1965 Feb; 15():165-71. PubMed ID: 14275273
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of computed tomography, magnetic resonance imaging, and localized 1H magnetic resonance spectroscopy in Canavan's disease: a case report.
    Marks HG; Caro PA; Wang ZY; Detre JA; Bogdan AR; Gusnard DA; Zimmerman RA
    Ann Neurol; 1991 Jul; 30(1):106-10. PubMed ID: 1929222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of human brain aspartate N-acetyl transferase flux in vivo.
    Burns SP; Chalmers RA; West RJ; Iles RA
    Biochem Soc Trans; 1992 May; 20(2):107S. PubMed ID: 1397517
    [No Abstract]   [Full Text] [Related]  

  • 7. Proton NMR spectroscopy of Canavan's disease.
    Barker PB; Bryan RN; Kumar AJ; Naidu S
    Neuropediatrics; 1992 Oct; 23(5):263-7. PubMed ID: 1454147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Magnetic resonance tomography and localized proton spectroscopy in 2 siblings with Canavan's disease].
    Engelbrecht V; Rassek M; Gärtner J; Kahn T; Mödder U
    Rofo; 1995 Sep; 163(3):238-44. PubMed ID: 7548871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPONGY DEGENERATION OF THE NERVOUS SYSTEM (CANAVAN'S DISEASE).
    HOGAN GR; RICHARDSON EP
    Pediatrics; 1965 Feb; 35():284-94. PubMed ID: 14261965
    [No Abstract]   [Full Text] [Related]  

  • 10. A radiometric assay for aspartoacylase activity in human fibroblasts: application for the diagnosis of Canavan's disease.
    Barash V; Flhor D; Morag B; Boneh A; Elpeleg ON; Gilon C
    Clin Chim Acta; 1991 Sep; 201(3):175-81. PubMed ID: 1756590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Canavan's disease: apropos of a case].
    del Moral García T; Rodríguez Arias C; Muñoz Sánchez-Reyes MD; López Muñoz J
    An Esp Pediatr; 1988 Oct; 29(4):327-9. PubMed ID: 3232881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR spectroscopic findings in a case of Alpers-Huttenlocher syndrome.
    Flemming K; Ulmer S; Duisberg B; Hahn A; Jansen O
    AJNR Am J Neuroradiol; 2002 Sep; 23(8):1421-3. PubMed ID: 12223390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetylaspartic aciduria due to aspartoacylase deficiency--a new aetiology of childhood leukodystrophy.
    Hagenfeldt L; Bollgren I; Venizelos N
    J Inherit Metab Dis; 1987; 10(2):135-41. PubMed ID: 3116332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic changes in the knockout mouse for Canavan's disease: implications for patients with Canavan's disease.
    Surendran S; Matalon KM; Szucs S; Tyring SK; Matalon R
    J Child Neurol; 2003 Sep; 18(9):611-5. PubMed ID: 14572139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [N-acetylaspartate is a biomarker of psychiatric and neurological disorders].
    Baymeeva NV; Miroshnichenko II
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(8):94-98. PubMed ID: 26356622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.
    Janson CG; Kolodny EH; Zeng BJ; Raghavan S; Pastores G; Torres P; Assadi M; McPhee S; Goldfarb O; Saslow B; Freese A; Wang DJ; Bilaniuk L; Shera D; Leone P
    Ann Neurol; 2006 Feb; 59(2):428-31. PubMed ID: 16437572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protracted form of Canavan's disease: case history and protein kinase activity of membrane fractions.
    Boehme DH; Marks N
    Acta Neuropathol; 1981; 55(3):221-5. PubMed ID: 7349580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal cell injury precedes brain atrophy in multiple sclerosis.
    Ge Y; Gonen O; Inglese M; Babb JS; Markowitz CE; Grossman RI
    Neurology; 2004 Feb; 62(4):624-7. PubMed ID: 14981182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computed tomography in the diagnosis of Canavan's disease.
    Andriola MR
    Ann Neurol; 1982 Mar; 11(3):323-4. PubMed ID: 7092188
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic assessment of the brain using proton magnetic resonance spectroscopy in a growth-restricted human fetus: case report.
    Azpurua H; Alvarado A; Mayobre F; Salom T; Copel JA; Guevara-Zuloaga F
    Am J Perinatol; 2008 May; 25(5):305-9. PubMed ID: 18437645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.